<DOC>
	<DOCNO>NCT01624727</DOCNO>
	<brief_summary>The purpose study target inflammation reduce progression noncalcified plaque coronary artery use intensive lifestyle intervention omega-3 fatty acid supplementation compare standard care .</brief_summary>
	<brief_title>Slowing HEART diSease With Lifestyle Omega-3 Fatty Acids</brief_title>
	<detailed_description>Study Design : This randomize , parallel study design usual care control group . 278 subject coronary heart disease ( CHD ) randomize intensive lifestyle intervention ( exercise nutrition counsel gear toward weight loss omega-3 supplementation ) standard care ( 139 arm ) . Multidetector compute tomographic angiography ( MDCTA ) perform baseline quantitate amount noncalcified calcified coronary plaque 30 month follow-up determine change volume noncalcified total plaque . The primary endpoint change coronary noncalcified plaque volume 30 month intervention active standard care . Hypothesis : Percent change progression coronary plaque volume less active lifestyle intervention compare standard care . Secondary endpoint include plasma level inflammatory marker , lipid measure insulin sensitivity . Secondary outcome include test hypothesis target inflammation lifestyle associate : 1 . Change total plaque volume per patient . 2 . Improvement metabolic syndrome assess measure waist/hip ratio , systolic diastolic blood pressure , lipid profile ( total cholesterol , triglyceride , HDL LDL ) , abdominal adiposity quantitated computerized tomography . 3 . Reduction mediator inflammation circulation include CRP , PAI-1 , serum amyloid A , MMP-9 fibrinogen , pro-inflammatory cytokine include IL-6 , TNF-a IL-1b , adhesion molecule VCAM-1 ICAM-1 , increase adiponectin reduction serum nitrotyrosine marker oxidative stress . 4 . Reduction insulin resistance assess fast insulin homeostasis model assessment insulin resistance ( HOMA-IR ) . 5 . Reduction inflammation liver associate nonalcoholic steatohepatitis ( NASH ) , newly recognize component metabolic syndrome , reduction fatty liver quantitated computerized tomography level AST ALT marker liver inflammation relate NASH . 6 . Comparison rate addition anti-hypertensive , diabetic , lipid lower medication . 7 . Comparison number person metabolic syndrome progress diabetes group . 8 . Comparison number person regress ATPIII metabolic syndrome criterion . 9 . Investigation relationship vitamin D status coronary calcification , well insulin resistance ( HOMA-IR ) , beta-cell function ( HOMA- % beta ) , serum level inflammatory cytokine adhesion molecule , know related CVD risk . 10 . Determination whether baseline vitamin D level predict clinical response lifestyle intervention , whether hypovitaminosis D associate plaque progression .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>1. coronary artery disease 2. previous myocardial infarction 3. angioplasty ( &gt; 6 month ago ) 4. previous coronary bypass surgery ( &gt; 12 month ago ) 5. stable angina 6. noncalcified plaque prior CT 7. abnormal exercise tolerance test 8. age 21 80 year 9 . BMI ≥ 27 kg/m2 ≤ 35 kg/m2 female ≤ 40 kg/m2 male ( BMI &gt; 24.5 subject Asian origin ) 10. stable dose statin 1 month screen unable tolerate statin 11. normal renal function estimate creatinine clearance calculate use CockcroftGault ( CG ) equation ≥60 screen [ eCrCLCG ( ml/min ) = [ ( 140 age ) x weight ( kg ) ] / [ SCr ( mg/dl ) x 72 ] x [ 0.85 female ] serum Cr &lt; 1.3 12 . ALT , AST ) &lt; 3 time upper limit normal ) 13. normal thyroid function stable dose replacement therapy 14. ETT perform within 12 month prior Exclusion criterion 1. unstable angina ( increase frequency severity anginal episode development chest pain rest ) 2. significant obstructive disease leave main coronary artery , ostial LAD newly diagnose threevessel disease since prior cardiac catheterization MDCTA 3. significant heart failure ( NYHA class III IV ) 4 . Current atrial fibrillation WolfParkinsonWhite ( WPW ) syndrome 5. allergy betablocker subject rest heart rate &gt; 65 bpm 6. systolic blood pressure &gt; 160 mm Hg 7. diastolic BP &gt; 100 mm Hg 8. person allergy iodinate contrast material shellfish 9. allergy nitroglycerin 10. history asthma unable tolerate betablockers 11 . BMI &gt; 35 kg/m2 female &gt; 40 kg/m2 male 12. body weight &gt; 350 lbs 13 . Use drug weight loss [ eg Xenical ( orlistat ) , Meridia ( sibutramine ) , Acutrim ( phenylpropanolamine ) similar overthecounter medication ] within three month screen 14. surgery within 30 day screen 15. history acquire immune deficiency syndrome human immunodeficiency virus ( HIV ) 16. poor mental function history dementia/Alzheimer 's Disease medication use treatment dementia [ e.g . Tacrine ( Cognex ) , Rivastigmine ( Exelon ) , Galantamine ( Razadyne , Reminyl ) , Donepezil ( Aricept ) , Memantine ( Namenda ) ] reason except patient difficulty comply requirement study 17. medicine erectile dysfunction within 72 hour prior MDCTA 18 . Prior stroke residual cognitive deficit functional deficit prevent type exercise 19 . Current chemotherapy radiation malignancy 20 . Current weekly alcohol consumption &gt; 21 units/week ( 1 unit = 1 beer , 1 glass wine , 1 mixed cocktail contain 1 ounce alcohol ) Exclusions base nuclear imaging : 1 . Transient cavity dilation 2 . More one vascular territory involve reversible defect ( multiple defect ) 3 . Reversible defect involve anterior wall , septum apex ( LAD territory ) Exclusions base echocardiography imaging : 1 . More one vascular territory involve inducible wall motion abnormality ( multiple defect ) 2 . Inducible wall motion abnormality involve anterior wall , septum apex ( LAD territory )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Coronary heart disease</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>CT angiography</keyword>
</DOC>